ATE208207T1 - Ein verfahren zum sensibilisieren von krebszellen zur durch killer-zellen vermittelte lyse - Google Patents

Ein verfahren zum sensibilisieren von krebszellen zur durch killer-zellen vermittelte lyse

Info

Publication number: ATE208207T1
Authority: AT; Austria
Prior art keywords: cells; pct; cancer cells; mediated lysis; killer cell
Prior art date: 1993-08-09

Application number

AT94922877T

Other languages

English (en)

Inventor

Edward Baral

Istvan Berczi

Eva Nagy

Lauri Kangas

Original Assignee

Edward Baral

Istvan Berczi

Eva Nagy

Orion Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-08-09

Filing date

1994-08-02

Publication date

2001-11-15

1994-08-02 Application filed by Edward Baral, Istvan Berczi, Eva Nagy, Orion Corp filed Critical Edward Baral

2001-11-15 Application granted granted Critical

2001-11-15 Publication of ATE208207T1 publication Critical patent/ATE208207T1/de

Links

206010028980 Neoplasm Diseases 0.000 title abstract 2
201000011510 cancer Diseases 0.000 title abstract 2
230000009089 cytolysis Effects 0.000 title abstract 2
230000001235 sensitizing effect Effects 0.000 title abstract 2
210000004027 cell Anatomy 0.000 abstract 5
229940046836 anti-estrogen Drugs 0.000 abstract 3
230000001833 anti-estrogenic effect Effects 0.000 abstract 3
239000000328 estrogen antagonist Substances 0.000 abstract 3
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 abstract 2
MKYQPGPNVYRMHI-UHFFFAOYSA-N Triphenylethylene Chemical group C=1C=CC=CC=1C=C(C=1C=CC=CC=1)C1=CC=CC=C1 MKYQPGPNVYRMHI-UHFFFAOYSA-N 0.000 abstract 1
210000003810 lymphokine-activated killer cell Anatomy 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
210000000822 natural killer cell Anatomy 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229960001603 tamoxifen Drugs 0.000 abstract 1
229960005026 toremifene Drugs 0.000 abstract 1
XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Developmental Biology & Embryology (AREA)
Biotechnology (AREA)
Hematology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT94922877T 1993-08-09 1994-08-02 Ein verfahren zum sensibilisieren von krebszellen zur durch killer-zellen vermittelte lyse ATE208207T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10351993A	1993-08-09	1993-08-09
PCT/FI1994/000333 WO1995004544A1 (en)	1993-08-09	1994-08-02	A method for sensitization of cancer cells for killer cell mediated lysis

Publications (1)

Publication Number	Publication Date
ATE208207T1 true ATE208207T1 (de)	2001-11-15

Family

ID=22295643

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT94922877T ATE208207T1 (de)	1993-08-09	1994-08-02	Ein verfahren zum sensibilisieren von krebszellen zur durch killer-zellen vermittelte lyse

Country Status (16)

Country	Link
US (1)	US5788964A (de)
EP (1)	EP0726772B1 (de)
JP (1)	JPH09501174A (de)
KR (1)	KR100340091B1 (de)
AT (1)	ATE208207T1 (de)
AU (1)	AU693459B2 (de)
CA (1)	CA2168584C (de)
CZ (1)	CZ285508B6 (de)
DE (1)	DE69429011T2 (de)
ES (1)	ES2167373T3 (de)
HU (1)	HUT74425A (de)
NO (1)	NO316823B1 (de)
NZ (1)	NZ269149A (de)
RU (1)	RU2153332C2 (de)
SK (1)	SK283124B6 (de)
WO (1)	WO1995004544A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6395494B1 (en)	1993-05-13	2002-05-28	Neorx Corporation	Method to determine TGF-β
US6117911A (en)	1997-04-11	2000-09-12	Neorx Corporation	Compounds and therapies for the prevention of vascular and non-vascular pathologies
HU223344B1 (hu) *	1997-08-13	2004-06-28	Máté Hidvégi	Immunstimuláns és metasztázist gátló fermentált, szárított anyag, ezt tartalmazó gyógyszerkészítmények, eljárás az előállítására és alkalmazásai
US20030130316A1 (en) *	2000-03-20	2003-07-10	Steiner Mitchell S.	Method for chemoprevention of prostate cancer
US20040092602A1 (en) *	1998-05-07	2004-05-13	Steiner Mitchell S.	Method for treatment and chemoprevention of prostate cancer
US6413533B1 (en)	1998-05-07	2002-07-02	The University Of Tennessee Research Corporation	Method for chemoprevention of prostate cancer
US20040176470A1 (en) *	1998-05-07	2004-09-09	Steiner Mitchell S.	Method for treatment and chemoprevention of prostate cancer
US6632447B1 (en)	1998-05-07	2003-10-14	The University Of Tennessee Research Corporation	Method for chemoprevention of prostate cancer
US6413535B1 (en)	1998-05-07	2002-07-02	The University Of Tennessee Research Corporation	Method for chemoprevention of prostate cancer
SI1003496T1 (en)	1998-05-07	2005-10-31	The University Of Tennessee Research Corporation	Medicament for treating prostate intraepithelial neoplasia
EP2213743A1 (de)	2000-04-12	2010-08-04	Human Genome Sciences, Inc.	Albuminfusionsproteine
CA2441228A1 (en) *	2001-03-23	2002-10-03	Aphton Corporation	Combination treatment of pancreatic cancer
US6613083B2 (en)	2001-05-02	2003-09-02	Eckhard Alt	Stent device and method
US20090191232A1 (en) *	2001-05-04	2009-07-30	Gevas Philip C	Combination therapy for the treatment of tumors
WO2002097038A2 (en) *	2001-05-25	2002-12-05	Human Genome Sciences, Inc.	Chemokine beta-1 fusion proteins
US20030021786A1 (en) *	2001-07-09	2003-01-30	Gevas Philip C.	Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
US20080249183A1 (en) *	2001-11-29	2008-10-09	Steiner Mitchell S	Treatment of androgen-deprivation induced osteoporosis
US6555095B1 (en)	2001-12-14	2003-04-29	Avon Products, Inc.	Topical compositions and methods of application
AU2002364586A1 (en)	2001-12-21	2003-07-30	Delta Biotechnology Limited	Albumin fusion proteins
WO2005003296A2 (en)	2003-01-22	2005-01-13	Human Genome Sciences, Inc.	Albumin fusion proteins
RU2209078C1 (ru) *	2002-02-28	2003-07-27	Институт биоорганической химии им. М.М.Шемякина и Ю.А.Овчинникова РАН	СОСТАВ ДЛЯ УНИЧТОЖЕНИЯ ФНО-α-ЧУВСТВИТЕЛЬНЫХ ОПУХОЛЕВЫХ КЛЕТОК
US20060020119A1 (en) *	2004-03-29	2006-01-26	Stephen Grimes	Monoclonal antibodies to gastrin hormone
WO2004088326A2 (en) *	2003-03-28	2004-10-14	Aphton Corporation	Gastrin hormone immunoassays
US7674460B2 (en) *	2003-08-01	2010-03-09	A&G Pharmaceutical, Inc.	Compositions and methods for restoring sensitivity to treatment with HER2 antagonists
RU2267326C2 (ru) *	2004-03-16	2006-01-10	ГУН НИИ онкологии им. проф. Н.Н. Петрова Минздрава РФ	Способ иммунотерапии опухолевым лизатом с адъювантом беталейкин больных солидными опухолями
DK1794586T3 (da) *	2004-09-22	2013-05-13	Cancer Advances Inc	Monoklonale antistoffer til progastrin
US20060270641A1 (en) *	2005-05-31	2006-11-30	Steiner Mitchell S	Method for chemoprevention of prostate cancer
RU2603742C2 (ru) *	2010-02-04	2016-11-27	Торэй Индастриз, Инк.	Фармацевтическая композиция для лечения и/или профилактики рака
KR20120093002A (ko) *	2011-02-14	2012-08-22	(주)에이티젠	Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
CA2971216A1 (en)	2014-12-23	2016-06-30	The Regents Of The University Of California	Methods for immunomodulation of cancer and infectious disease therapy
US12150978B2 (en)	2017-06-15	2024-11-26	Cancer Advances Inc.	Compositions and methods for preventing tumors and cancer
EP3624841A4 (de)	2017-06-15	2021-01-27	Cancer Advances, Inc.,	Zusammensetzungen und verfahren zur induzierung humoraler und zellulärer immunitäten gegen tumore und krebs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5024833A (en) *	1988-03-10	1991-06-18	Industrial Farmaceutica Serono Spa	Combined interferon/antiestrogen therapy for treatment of breast cancer
US5057423A (en) *	1987-12-18	1991-10-15	University Of Pittsburgh	Method for the preparation of pure LAK-active lymphocytes
US5189212A (en) *	1990-09-07	1993-02-23	University Of Georgia Research Foundation, Inc.	Triarylethylene carboxylic acids with estrogenic activity
EP0589039A1 (de) *	1991-04-30	1994-03-30	Asahi Kasei Kogyo Kabushiki Kaisha	Triphenylethylenderivate und sie enthaltende pharmazeutische präparation

1994
- 1994-08-02 KR KR1019960700689A patent/KR100340091B1/ko not_active Expired - Fee Related
- 1994-08-02 NZ NZ269149A patent/NZ269149A/en unknown
- 1994-08-02 AT AT94922877T patent/ATE208207T1/de not_active IP Right Cessation
- 1994-08-02 US US08/596,121 patent/US5788964A/en not_active Expired - Lifetime
- 1994-08-02 AU AU72637/94A patent/AU693459B2/en not_active Ceased
- 1994-08-02 EP EP94922877A patent/EP0726772B1/de not_active Expired - Lifetime
- 1994-08-02 SK SK180-96A patent/SK283124B6/sk unknown
- 1994-08-02 DE DE69429011T patent/DE69429011T2/de not_active Expired - Fee Related
- 1994-08-02 RU RU96105946/14A patent/RU2153332C2/ru not_active IP Right Cessation
- 1994-08-02 WO PCT/FI1994/000333 patent/WO1995004544A1/en not_active Ceased
- 1994-08-02 CZ CZ96316A patent/CZ285508B6/cs not_active IP Right Cessation
- 1994-08-02 JP JP7506232A patent/JPH09501174A/ja active Pending
- 1994-08-02 CA CA002168584A patent/CA2168584C/en not_active Expired - Lifetime
- 1994-08-02 HU HU9600294A patent/HUT74425A/hu unknown
- 1994-08-02 ES ES94922877T patent/ES2167373T3/es not_active Expired - Lifetime
1996
- 1996-02-08 NO NO19960511A patent/NO316823B1/no unknown

Also Published As

Publication number	Publication date
HUT74425A (en)	1996-12-30
NO960511D0 (no)	1996-02-08
CZ31696A3 (en)	1997-03-12
JPH09501174A (ja)	1997-02-04
NO316823B1 (no)	2004-05-24
RU2153332C2 (ru)	2000-07-27
AU7263794A (en)	1995-02-28
NZ269149A (en)	1997-06-24
CZ285508B6 (cs)	1999-08-11
US5788964A (en)	1998-08-04
AU693459B2 (en)	1998-07-02
HU9600294D0 (en)	1996-04-29
EP0726772B1 (de)	2001-11-07
EP0726772A1 (de)	1996-08-21
NO960511L (no)	1996-02-08
CA2168584A1 (en)	1995-02-16
SK18096A3 (en)	1996-11-06
SK283124B6 (sk)	2003-02-04
KR960703616A (ko)	1996-08-31
DE69429011D1 (de)	2001-12-13
WO1995004544A1 (en)	1995-02-16
ES2167373T3 (es)	2002-05-16
DE69429011T2 (de)	2002-07-11
CA2168584C (en)	2008-10-14
KR100340091B1 (ko)	2002-09-27

Legal Events

Date	Code	Title	Description
2002-05-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE208207T1 (de)	2001-11-15	Ein verfahren zum sensibilisieren von krebszellen zur durch killer-zellen vermittelte lyse
CO4290417A1 (es)	1996-04-17	Nuevas benzoilguanidinas como medicamentos y su preparacion .
ZA963593B (en)	1996-11-25	IL-6 activity inhibitor
DE69520668D1 (de)	2001-05-17	Antimikrobielle zubereitungen mit breitem spektrum und verfahren zu ihrer nutzung
NO955047D0 (no)	1995-12-13	Sekundære aminer som antidiabetiske og antifedme-midler
NZ285846A (en)	2000-01-28	Arylsulphonamido-substituted hydroxamic acids and preparation and medicaments useful for inhibiting metalloproteinases
AR018501A1 (es)	2001-11-28	Derivados de la dolastatina 15
Kuehl	1979	Synthesis of high mobility group proteins in regenerating rat liver.
GEP20022680B (en)	2002-04-25	Carbocyclic Nucleoside Hemisulfate, Method for Its Production, Its Use for Treatment of Viral Infections and Pharmaceutical Composition Containing the Same
ATE71110T1 (de)	1992-01-15	Verfahren zur reinigung eines proteins.
Green et al.	1987	Twenty years of treating decompression sickness
ATE248914T1 (de)	2003-09-15	Allogenes vakzin und synthesemethode für selbiges
EP0324447A3 (de)	1990-01-31	Mittel und Verfahren zur Herstellung eines rekombinanten, menschlichen Interleukin-1 alpha-Polypeptides
DK0658117T3 (da)	1999-02-01	Behandling af tumorer med neurotrofe faktorer og celleproliferationsinhibitorer
GR3024660T3 (en)	1997-12-31	Distillative method of recovering glycols from used antifreeze agents
RU94044323A (ru)	1996-11-10	Средство ингибирования навязчиво-компульсивных состояний и расстройств потребления
SG52658A1 (en)	1998-09-28	Tryptase inhibitor
BRPI0408984A (pt)	2006-03-28	método para tratar uma condição de doença mediada por células neutrofìlicas em um paciente, e, uso de um composto de ligação de histamina
ATE279521T1 (de)	2004-10-15	Regulierende nukleinsaeuresequenzen und verwendungen
DE69838002D1 (de)	2007-08-09	Substituierte 11-phenyl-dibenzazepin-verbindungen, die nützlich sind zur behandlung oder vorbeugung von durch abnormale zellproliferation gekennzeichneten krankheiten
ES8506710A1 (es)	1985-08-01	Procedimiento para la obtencion de teofilin-7-acetato de ambroxol
ATE269090T1 (de)	2004-07-15	Tiermodell zum testen von arzneistoffen zur behandlung von leukämie oder hiv
Davidson	1982	THE EFFECTS OF PLACEMENT SERVICES ON JOBS CORPS PARTICIPANTS'POST-PROGRAM LABOR MARKET EXPERIENCES.
Posel	1949	Radiological case book: XXI: a case of hemiparalysis of the diaphragm
AU570820B2 (en)	1988-03-24	1-(n-(alpha-amino-alpha-methylacetyl)-4-aminophenyl)-2- aminopropanone derivatives